14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CON vs ARDT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CON Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)
CON Overall Winner
6-Pillar Tally: CON 4 – 2 ARDT
Matrix Metrics: CON 8 – 2 ARDT
As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Ardent Health, Inc. (ARDT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas ARDT carries 40.2/100 (SELL) at $15.08 (10.9x Forward P/E, 5.1% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CON vs ARDT. Trailing 12-month operating profitability (CON 17.2% vs ARDT 5.1%) and valuation multiples (CON 22.0x vs ARDT 10.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Care Facilities value chain with $2.0B market capitalization and 5.1% operating margin.
OpEx & R&D Reinvestment54.0% of Rev ($3.49B)
90D Engineering Disclosures0 Published
Investor FAQ CON vs ARDT Key Questions & Quantitative Answers
As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Ardent Health, Inc. (ARDT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas ARDT carries 40.2/100 (SELL) at $15.08 (10.9x Forward P/E, 5.1% operating margin). Technically, CON sits in a Markup phase (RSI 55.6, BREAKOUT options structure) and ARDT sits in a Markup phase (RSI 52.8, UNCLASSIFIED options structure).
CON leads the Growth & Scale pillar: CON posts +8.6% YoY revenue growth and +36.4% YoY earnings growth on $2.34B TTM revenue (29.9% gross margin, 17.2% operating margin), compared with ARDT at +3.1% YoY revenue growth and -77.1% YoY earnings growth on $6.45B TTM revenue (59.1% gross margin, 5.1% operating margin). On trailing 12-month operating scale, CON generates $2.34B in USD-normalized revenue versus $6.45B for ARDT. In operating R&D and SG&A reinvestment, CON deploys 12.7% of Rev ($297M) (0 90-day corporate R&D disclosures) versus 54.0% of Rev ($3.49B) (0 disclosures) for ARDT.
ARDT screens cheaper on headline valuation multiples. CON trades at 22.0x Forward P/E, 24.5x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (11.0% FCF margin), whereas ARDT trades at 10.9x Forward P/E, 14.1x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (7.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CON (47.2% ROE) versus ARDT (13.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CON carries 269.9% implied volatility (95th %ile, Extreme (>80th %ile)), a 0.79x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (0.52β · 38% Vol realized risk). By comparison, ARDT carries 53.1% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.01β · 115% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.